Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-Amino-6-cyclohexyl-4-hydroxy-2-isobutyl‑hexanoic acid is a synthetic small molecule classified as a delta amino acid derivative. Its molecular formula is C16H31NO3 and it has a molecular weight of approximately 285.42 g/mol[1][3][4]. The compound features an amino group at the 5-position, a cyclohexyl group at the 6-position, a hydroxy group at the 4-position, and an isobutyl side chain at the 2-position on its hexanoic acid backbone[9]. It has been catalogued in chemical and drug databases as an experimental compound but does not have any approved medical indications or known clinical development activity beyond preclinical/experimental status[1]. No mechanism of action or biological target has been established for this molecule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-amino-6-cyclohexyl-4-hydroxy-2-isobutyl-hexanoic acid.